A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-30

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. Traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. At present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in China. However, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. Therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions

NCT00001291

Arthritis, Psoriatic Autoimmune Diseases Joint Diseases +2 more

COMPLETED

Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)

NCT00111410

Rheumatoid Arthritis

COMPLETED PHASE4

To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS

NCT02311842

Ankylosing Spondylitis

COMPLETED

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

NCT00000433

Spondylitis, Ankylosing

COMPLETED PHASE2

Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"

NCT02878161

Rheumatoid Arthritis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankylosing Spondylitis (AS) Psoriatic Arthritis (PsA) Nr-axSpA Polymyalgia Rheumatica (PMR) Takayasu Arteritis (TAK) Giant Cell Arteritis (GCA) Behcet's Disease Enthesitis-related Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis/radiologically negative axial spondyloarthritis/psoriatic arthritis/polymyalgia rheumatica/Takayasu arteritis/giant cell arteritis/ non-ocular Behcet's disease/ enthesitis-related arthritis;
2. Currently receiving or planning to receive fulvezinib treatment;
3. Can follow up according to the doctor's advice;
4. Able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study.